Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency

Clinical trial NCT01230021 · COMPLETED

Trial details

NCT number: NCT01230021
Sponsor: Novo Nordisk A/S
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Congenital Bleeding Disorder Congenital FXIII Deficiency

Start date: 2010-11-01
Primary completion: 2012-01-01
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.